Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies.
about
The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway.Pathways to tamoxifen resistance.Identification of functional networks of estrogen- and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer.Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cellsEstrogen receptor silencing induces epithelial to mesenchymal transition in human breast cancer cells.Structural insights into selective agonist actions of tamoxifen on human estrogen receptor alpha.Tribbles homolog 3 denotes a poor prognosis in breast cancer and is involved in hypoxia response.Headway in resistance to endocrine therapy in breast cancer.New and emerging radiosensitizers and radioprotectors.Different Expression of Extracellular Signal-Regulated Kinases (ERK) 1/2 and Phospho-Erk Proteins in MBA-MB-231 and MCF-7 Cells after Chemotherapy with Doxorubicin or DocetaxelHormonally responsive breast cancer cells in a microfluidic co-culture model as a sensor of microenvironmental activity.Progressive increase of glucose transporter-3 (GLUT-3) expression in estrogen-induced breast carcinogenesis.Calmodulin modulates Akt activity in human breast cancer cell lines.Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cellsExpression of a phosphorylated p130(Cas) substrate domain attenuates the phosphatidylinositol 3-kinase/Akt survival pathway in tamoxifen resistant breast cancer cells.Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications.Synthetic cajanin stilbene acid derivatives inhibit c-MYC in breast cancer cells.Reactivation of p53 by MDM2 Inhibitor MI-77301 for the Treatment of Endocrine-Resistant Breast Cancer.Flaxseed cotyledon fraction reduces tumour growth and sensitises tamoxifen treatment of human breast cancer xenograft (MCF-7) in athymic mice.Inhibition of focal adhesion kinase suppresses the adverse phenotype of endocrine-resistant breast cancer cells and improves endocrine response in endocrine-sensitive cells.Dietary flaxseed interaction with tamoxifen induced tumor regression in athymic mice with MCF-7 xenografts by downregulating the expression of estrogen related gene products and signal transduction pathways.Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells.A suppressive role of guanine nucleotide-binding protein subunit beta-4 inhibited by DNA methylation in the growth of anti-estrogen resistant breast cancer cells
P2860
Q30425478-F22DD0B0-E4BA-46AB-A1B4-EC6C948FE985Q30441001-556A01ED-98DE-42FC-A545-99D0B7DFBAA3Q33361574-23DEBE97-6458-4711-AF7B-032C4337CCE8Q33648503-99AFB139-3632-4444-8EDE-6B6D41370486Q33928138-7988DBA2-AAFC-4546-B5D3-326D8EBF067AQ33945493-AA36D39C-A3B5-4F76-8169-C62C58EF0D43Q35233145-353338C8-1B35-4896-A832-D282D93511BFQ35608727-3D25AFCC-8CB0-434B-8C8A-7D938ABBF73EQ35667708-935FF26D-5D83-4FFC-8687-DCE42DAE0F35Q36508097-6898C934-08F5-4231-9ACD-98AF7A86F907Q36652542-9042E1C8-5812-478B-B6F6-BE7F5E3600E6Q36827824-38C6F888-DAE3-4469-A4AD-7E8B56D5BA13Q37062935-EB555EF2-6423-400F-89C3-CF4540D1EE58Q37078493-4C007F90-42C0-4696-B6D7-AFF0EC62B14FQ37131348-9A6F6F5D-7A35-46C5-B360-C29B7798BF42Q37345203-3E525E37-802E-41AE-A6CC-6756D92AE626Q38125970-F1DE97DE-55F7-4B50-81D9-B774A8C4FCEDQ38300836-B4577F2D-8516-4345-81EB-D072AC1A2528Q38739252-CC6CF765-A170-46F3-BF34-5AA28B80818BQ39622903-E145F69D-7DCD-4E97-B2AF-3569B3F5EC05Q39720714-51706163-4967-46CC-89C6-786A24772336Q40105157-07953EA8-9286-44F9-AC34-25699580B5BBQ42563273-286687DB-30E8-4C25-8F03-FD646A40A4A1Q58786580-4A02FA73-CD7D-4D1D-A294-2680EA801F14
P2860
Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Growth factor signalling netwo ...... s: new therapeutic strategies.
@ast
Growth factor signalling netwo ...... s: new therapeutic strategies.
@en
type
label
Growth factor signalling netwo ...... s: new therapeutic strategies.
@ast
Growth factor signalling netwo ...... s: new therapeutic strategies.
@en
prefLabel
Growth factor signalling netwo ...... s: new therapeutic strategies.
@ast
Growth factor signalling netwo ...... s: new therapeutic strategies.
@en
P2093
P1476
Growth factor signalling netwo ...... ts: new therapeutic strategies
@en
P2093
Hutcheson IR
Knowlden JM
Nicholson RI
P304
P356
10.1016/J.JSBMB.2004.12.006
P577
2005-02-08T00:00:00Z